A 4-year study involving a 2 x 2 factorial randomized clinical trial (RCT) is proposed to investigate quality of life (QOL) effects of: (1) an intensive program of ovarian cancer screening including transvaginal sonography (TVS) and annual CA125, staggered so that a woman is screened by one or the other modality every 6 months, and (2) group counseling specifically designed to reduce ovarian cancer- releated anxiety through risk education and psychological support. Hypotheses to be tested are driven by a self-regulation model or health behavior developed by leventhal. About 320 women with a family history of ovarian cancer and 160 average-risk women will be recruited directly and through their physicians to participate in the RCT. Screening for ovarian cancer is not currently recommended because the disease is rare, screening efficacy has not been demonstrated, and false positive test results may lead to surgery which carries its own risks. However, guidelines consistently suggest that risk assessment according to family history is needed and that women from families with histories indicative of hereditary cancer syndrome should undergo some form of regular screening. They offer no guidance regarding how remaining patients' distress about their risk for ovarian cancer should be addressesd. The study addresses the relative efficacy of group risk education counseling and intensive screening in reducing cancer-related worry and improving QOL. Women at significant risk of carrying a dominant cancer susceptibility gene will be identified so that the effects of individualized genetic counseling on their QOL can be studied as will. The evaluation plan includes an exploratory piece to estimate the """"""""shape"""""""" of the QOL line over the intervention period, as well as methods to assess the change in QOL over the period. QOL is measured by the RAND-36, which incorporates physical, social, and psychological functioning, and the level of distress attributable to ovarian cancer worry and ovarian-cancer-related events. Distress will be measured on random days throughout the intervention period as well as at baseline and follow-up. A cost-effectiveness component is included in the evaluation plan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA075494-03
Application #
2896169
Study Section
Behavioral Medicine Study Section (BEM)
Program Officer
Nelson, Wendy
Project Start
1997-09-15
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Shah, Chirag A; Lowe, Kimberly A; Paley, Pamela et al. (2009) Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 18:1365-72
Scholler, Nathalie; Lowe, Kimberly A; Bergan, Lindsay A et al. (2008) Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res 14:2647-55
Palmer, Chana; Duan, Xiaobo; Hawley, Sarah et al. (2008) Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 3:e2633
Andersen, M Robyn; Drescher, Charles W; Zheng, Yingye et al. (2007) Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology 16:814-20
Drescher, Charles W; Nelson, Judy; Peacock, Sue et al. (2004) Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev 13:600-6
Andersen, M Robyn; Nelson, Judy; Peacock, Sue et al. (2004) Worry about ovarian cancer risk and use of screening by high-risk women: how you recruit affects what you find. Am J Med Genet A 129A:130-5
McIntosh, M W; Drescher, C; Karlan, B et al. (2004) Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 95:9-15
McIntosh, Martin W; Urban, Nicole (2003) A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 4:27-40
Andersen, M R; Peacock, S; Nelson, J et al. (2002) Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer. Gynecol Oncol 85:3-8
Kneipp, S M; McIntosh, M (2001) Handling missing data in nursing research with multiple imputation. Nurs Res 50:384-9

Showing the most recent 10 out of 11 publications